UNI-BIO SCIENCE GROUP LTD SHS CAYMAN I overview

EQS Newswire / 02/07/2025 / 09:56 UTC+8 On June 27, 2025, Uni-Bio Science Group Limited (the “ Group ” )grandly held a new medical aesthetics product launch event in Changsha, releasing the high-end series GeneQueens of 肌顏態 ® and the medical device brand 金因敷 ® . Many experts, KOLs and partners attended the event. This launch not only showcased the Group's achievements in R&D, but also marked the comprehensive layout in the "drug, medical device and Aesthetics" field. （ Photo:...

EQS Newswire / 21/05/2025 / 19:12 UTC+8 21 May 2025 – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”) proudly announces that its new ophthalmology product, 金因康 ® (Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字 H20254149]. This milestone strengthens the Group’s portfolio in ophthalmology, addressing the growing demand for...

EQS Newswire / 27/03/2025 / 22:30 UTC+8 Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share Strengthening Presence in Osteoporosis, Ophthalmology, and Aesthetic Medical Markets (27 March 2024 – Hong Kong) A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results...

EQS Newswire / 02/12/2024 / 18:14 UTC+8 2nd December 2024 –Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce two significant milestones that demonstrate the Group’s continued growth and innovation in the field of medical aesthetics and dermatological solutions. The Group ’ s strategic cooperation product with Chongqing Minji Medical Device Co., Ltd., recombinant collagen dressing, has successfully received Class II...

EQS Newswire / 28/08/2024 / 19:52 UTC+8 Achieved Record High Revenue of HK$273.6M and Net Profit of HK$67.4M Further Penetration to Osteoporosis, Ophthalmology, and Medical Aesthetic Device Markets (28 August 2024 – Hong Kong) A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2024...

EQS Newswire / 10/07/2024 / 13:17 UTC+8 Recently, Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries (Beijing Genetech, Shenzhen Watsin, Dongguan Watsin), the “Group”) is pleased to announce a strategic cooperation with Chongqing Minji Medical Device Co., Ltd. (hereafter "Chongqing Minji"). This partnership expands the Group's business into the medical aesthetics device sector and enhances its long-term strategy in biopharmaceuticals and medical aesthetics. In...